1 / 23

The Challenge of Health Care in Europe: “value for money ”

The Challenge of Health Care in Europe: “value for money ”. Professor Peter Littlejohns BSc MBBS MD FRCP FFPH FRCGP Clinical and Public Health Director. Overview of presentation. The challenge NICE: brief history and emerging new role A new research programme.

zuwena
Télécharger la présentation

The Challenge of Health Care in Europe: “value for money ”

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Challenge of Health Care in Europe: “value for money” Professor Peter Littlejohns BSc MBBS MD FRCP FFPH FRCGP Clinical and Public Health Director

  2. Overview of presentation • The challenge • NICE: brief history and emerging new role • A new research programme

  3. Patient confidence that they will receive the most effective care

  4. Opportunity costs You can only spend one healthcare pound or euro once. Within in a fixed budget if a health care system spends more on one thing, it has to do less of something else The ‘opportunity cost’ is the value of the best alternative use of resources

  5. “What is the most difficult ethical dilemma facing society and science today?”Exchange recorded in The Guardian Weekend magazine 11 September 2010 How far do you go to preserve individual human life? I mean, what are we to do with the NHS? How can you put a value in pounds, shillings and pence on an individuals life? There was a case with a bowel cancer drug – if you gave that drug, which costs several thousand pounds, it continued life for six weeks. How can you make that decision?” Sir David Attenborough, Naturalist “Yes, that is a good one” Richard Dawkins, Evolutionary biologist

  6. Action at all levels of the system

  7. The National Institute for Health and Clinical Excellence (NICE) NICE is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health. It was established in 1999 as a Special Authority and in 2005 it was expanded to include the functions of Health Development Agency. In 2012 (subject to legislation) it will become the National Institute for Health and Care Excellence and cover social care

  8. The Institute encourages cost effective practice by issuing guidance in three areas • Public health – guidance on the promotion of good health and the prevention of ill health for those working in the NHS, local authorities and the wider public and voluntary sector • Health technologies– guidance on the use of new and existing medicines, treatments and procedures within the NHS including interventional procedures, diagnostics and devices • Clinical practice– guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS.

  9. Core principles underpinningall NICE guidance • Comprehensive evidence base • Expert input • Patient and carer involvement • Independent advisory committees • Genuine consultation • Regular review • Open and transparent process

  10. William Blake – English Poet and Artist NICE makes scientific and social values judgements “God forbid that truth should be confined to mathematical demonstration ”

  11. A short history of NICE Interventional Procedures Quality standards QOF Clinical guidelines Public health

  12. NICE’s new role in the NHS Outcomes Framework

  13. Value Based Pricing The UK Government view: “We need a system that encourages the development of breakthrough drugs addressing areas of significant unmet need. And we need a much closer link between the price the NHS pays and the value a new medicine delivers, sending a powerful signal about the areas that the pharmaceutical industry should target for development.” “Over the next three years we will be moving towards a new system of pricing for medicines, where the price of a drug will be determined by its assessed value.”

  14. Working with Policy-Makers around the World Kalipso Chalkidou

  15. Empowers decision makers in low and middle income countries by identifying and helping them to act on their own policy priorities Focuses on institutional structure, longer-term capacity building and system governance Offers collaborative problem-solving and hands-on support, drawing on people and experience, from the UK and abroad, to adapt evidence and policies to countries’ local context

  16. Exploring opportunities or strengthening institutional links Active or completed projects

  17. Thank you for your attention

More Related